Добавил:
kiopkiopkiop18@yandex.ru t.me/Prokururor I Вовсе не секретарь, но почту проверяю Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз: Предмет: Файл:
Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_5786_Библиотеки_им_академика_М_И_Перельмана.pdf
Скачиваний:
0
Добавлен:
31.08.2026
Размер:
39 Мб
Скачать
✩ ✩✩✩✩✩✩✩✩✩✩
Hyperechogenic bowel
This is found in about 0.5% of fetuses and is usually of no pathological signifi­cance. The commonest cause is intra-amniotic bleeding but occasionally it may be a marker of cystic fibrosis or chromosomal defects. For isolated hyperecho­genic bowel the risk for trisomy 21 may be seven times the background.
Short femur
If the femur is below the fifth centile and all other measurements are normal, the baby is likely to be normal but rather short. Rarely this is a sign of dwarfism. Occasionally it may be a marker of chromosomal defects. On the basis of exist­ing studies, short femur is found four times as commonly in trisomy 21 fetuses compared to normal fetuses. However, there is some evidence that isolated short femur may not be more common in trisomic than normal fetuses.
Echogenic foci in the heart
These are found in about 4% of pregnancies and they are usually of no pathologi­cal significance. However, they are sometimes associated with cardiac defects and
Ultrasound in obstetrics and gynaecology
chromosomal abnormalities. For isolated hyperechogenic foci the risk for trisomy 21 may be three times the background.
Choroid plexus cysts
These are found in about 1–2% of pregnancies and they are usually of no patho­logical significance. When other defects are present there is a high risk of chromo­somal defects, usually trisomy 18 but occasionally trisomy 21. For isolated choroid plexus cysts the risk for trisomy 18 and trisomy 21 is 1.5 times the background.
204
Mild hydronephrosis
This is found in about 1–2% of pregnancies and is usually of no pathological sig­nificance. When other abnormalities are present there is a high risk of chromo­somal defects, usually trisomy 21. For isolated mild hydronephrosis the risk for trisomy 21 is 1.5 times the background.

ACCURACY OF ULTRASOUND IN THE DETECTION OF FETAL ANOMALIES

In the 1980s, there were great expectations that the systematic use of ultrasound would allow recognition of most fetal anomalies. In most European countries, an obstetric sonogram at midgestation rapidly became the standard of care. However, the results of the available studies variations (Table 10.3). The disappointing sensitivities of some studies were prob- ably the consequence of inadequate expertise of the operators and it is reassur­ing to note a progressive improvement throughout the years. Most of the studies published in the late 1990s described sensitivities in excess of 50%. A word of caution is, however, necessary. Some of the series with the best results had an unusually low prevalence of anomalies at birth, in the region of 1%. These low
18–27
demonstrate great national and regional
✩✩✩✩✩✩✩✩✩✩ ✩
Table 10.3 Studies documenting the results of routine obstetric ultrasound for the detection of fetal anomalies
Study
Rosendahl 1989
Saari-Kemppainen
23
1990
Chitty 1991
Levi 1992 15,654 2.3 0.21 1.00 4
Shirley 1992
Luck 1992
Ewigmann 7617 2.46 0.17 4
Levi 1995
Boyd 1998
Whitlow 1999
19
26
22
21
18
27
Cases
25
9012 1.03 0.39 0.999 4
4691 0.43 0.47 0.998 2
8785 1.5 0.74 0.999 11
6412 1.4 0.60 0.999 8
8844 1.9 0.85 0.999 16
9392 2.45 0.41 0.999 9
33,376 2.17 0.55 0.995 11
6443 1.4 0.81 0.999 8
Prevalence of anomalies at birth (%)
Sensitivity
Specificity
Anomalies detected per 1000 pregnancies
figures may be the consequence of incomplete postnatal ascertainment, which of course would lead to overestimation of the real sensitivity of antenatal studies.
At the time of writing, the accuracy of ultrasound in detecting fetal anomalies remains a subject of debate in the literature. Fetal ultrasound is clearly the com­bination of sophisticated technology and skilled medical craftsmanship, strictly intertwined. The ability to detect fetal anatomical defects depends largely upon the operator's skills and expertise. It is clear that despite the quality of instru­mentation and the ability of the operator, a reasonable proportion of fetal anoma­lies will be missed. The remarkable results of pilot studies performed in referral centres are largely due to the selection of patients. Such studies include large numbers of pregnancies in which either a fetal anomaly had been previously suspected during a basic scan or there was a family history of anomalies ame­nable to ultrasound diagnosis. Independently from the expertise of the operator or the equipment used, some fetal anomalies will not be detectable in utero or in early gestation due to either late development or limitations of current ultra­sound technology. Examples of the former group of lesions include persistence of the fetal circulation, disruptions (porencephaly, migrational disorders), tumours, intestinal obstructions, urinary tract dilation and many types of skeletal dyspla­sias. Examples of the latter group include ventricular and atrial septal defects. Given the heterogeneity of congenital anomalies, in many cases it remains diffi­cult to establish whether a specific condition can be recognized in early gestation or not. Indeed, even within the same centre indicated sonograms result in a much greater sensitivity than screening examination performed on low-risk patients.
28
One important problem that is surfacing and that needs to be addressed when establishing a program of ultrasound screening in pregnancy is the issue of the so-called soft markers. This term is commonly employed to define an ultrasound
Prenatal diagnosis of fetal anomalies
205
✩ ✩✩✩✩✩✩✩✩✩✩
finding that is not abnormal per se but increases the likelihood of a fetal anomaly, most frequently a chromosomal aberration. An increased nuchal fold or a chor­oid plexus cyst represents a typical example. The surveys on the systematic use of ultrasound in pregnant patients in the 1980s and early 1990s were at variance in the sensitivity, but luckily specificity was invariably high in all studies, no mat­ter the type of population scanned or the ultrasonographic expertise of those performing the examinations. False positives occurred in less than 1 case in 1000 patients. It was reassuring to know that although anomalies could be missed, they were very rarely overdiagnosed. While a false-negative diagnosis may leave the family with the emotional, medical, social and economic burdens imposed by a child born with a congenital anomaly, false-positive diagnoses may be ominous as well since they may lead to termination of a normal fetus.
In one recent study, soft markers were responsible for a false-positive rate greater than 1 in 200.18 Although it is debatable whether a soft marker should be considered a false positive or more simply a risk factor for further investigation, there is no doubt that they can cause a great deal of parental anxiety.
Ultrasound in obstetrics and gynaecology
The available experience on soft markers is conflicting. Different research­ers have reported different results, many different markers have been described, and some of them have subjective definitions (e.g. hyperechogenic bowel). A review of the literature suggested that the use of soft markers in low-risk patients allows detection of some fetal anomalies, but at the same time results in severe anxiety for a number of couples and increases the number of invasive tests. In the study previously quoted, soft markers increased the sensitivity of the midtri­mester sonogram from 51% to 55% but at the same time they increased 12-fold the false-positive rate, from 1 in 2332 to 1 in 188.18 At present there is a lack of consensus on whether soft markers should be employed in low-risk patients, and if so, which soft markers should be used and how the patients should be coun-
30
selled.
As this is likely to become one of the most critical issues in the future of obstetric ultrasound, every ultrasound laboratory should establish its own policy. The most important variables to consider in establishing such a policy include the expectations of the population that is undergoing the ultrasound examination, the experience of the operators, the availability of other screening programmes such as nuchal translucency at 11–14 weeks’ scan and maternal biochemistry that has been demonstrated to be more reproducible.
29
206

CONCLUSION

A careful ultrasound examination of the midtrimester fetus, performed with current ultrasound technology by an expert examiner, allows the detection of many anoma­lies, probably in the range of 50% of those that can be identified at birth. The sys­tematic use of a well-defined set of qualitative as well as quantitative parameters is critical for the good result of the examination. Some areas of fetal anatomy remain difficult to evaluate, the most remarkable example being the heart. It is expected that advances in the technology of diagnostic ultrasound, better training and increas­ing awareness of the operators will further improve the current standards.
✩✩✩✩✩✩✩✩✩✩ ✩

Note

Further images relating to this chapter are found on the CD accompanying this book.

References

Prenatal diagnosis of fetal anomalies
1. Romero R, Pilu G, Jeanty P, Ghidini A, Hobbins JC. Prenatal diagnosis of congenital anomalies. Appleton and Lange, Norwalk, CT, 1988
2. Nyberg D, Mahony BS, Pretorius D. Diagnostic ultrasound of fetal anomalies: text and atlas. Year Book Medical Publishers, Chicago, 1990
3. Pilu G, Nicolaides KH. Diagnosis of fetal abnormalities. The 18–23 week scan. Parthenon Publishing, London, 1999
4. Nyberg D, McGahan J, Pretorius D, Pilu G. Diagnostic ultrasound of fetal anomalies. Lippincott, Williams and Wilkins, Philadelphia, 2001
5. Kalter H, Warkany J. Medical progress. Congenital malformations: etiologic factors and their role in prevention (first of two parts). N Engl J Med 1983;308:24–31
6. Kalter H, Warkany J. Congenital malformations (second of two parts). N Engl J Med 1983;308:91–97
7. Leck I. Fetal malformations. In: Barron SL, Thomson AM (eds) Obstetrical epidemiology. Academic Press, London, 1983: 263–318
8. CDC. Achievements in public health, 1900–1999: healthier mothers and babies. MMWR 1999;48(38):849–857
9. CDC. Contribution of birth defects to infant mortality – United States, 1986. MMWR 1989;38:633
10. Anderson RN, Kochanek KD, Murphy SL. Report of the final mortality statistics, 1995. US Department of Health and Human Services, CDC, National Center for Health Statistics, Hyattsville, MD, 1997
11. Ventura SJ, Martin JA, Curtin SC, Mathews TJ. Report of final natality statistics, 1995. US Department of Health and Human Services, CDC, National Center for Health Statistics, Hyattsville, MD, 1997
12. National Center for Health Statistics. Vital statistics of the United States, 1968, vol II, mortality, part A. US Department of Health, Education and Welfare, Public Health Service, CDC, Rockville, MD, 1972
13. Filly RA, Cardoza JD, Goldstein RB, Barkovich AJ. Detection of fetal central nervous system anomalies: a practical level of effort for a routine sonogram. Radiology 1989;172(2):403–408
14. Copel JA, Pilu G, Green J, Hobbins JC, Kleinman CS. Fetal echocardiographic screening for congenital heart disease: the importance of the four-chamber view. Am J Obstet Gynecol 1987;157(3):648–655
15. Buskens E, Grobbee DE, Frohn-Mulder IM et al. Efficacy of routine fetal ultrasound screening for congenital heart disease in normal pregnancy. Circulation 1996;94(1):67–72
16. Tegnander E, Williams W, Johansen OJ, Blaas HJ, Eik-Nes SH. Prenatal detection of heart defects in a non-selected population of 30,149 fetuses – detection rates and outcome. Ultrasound Obstet Gynecol 2006;27:252–265
17. Allan L, Benacerraf B, Copel JA et al. Isolated major congenital heart disease. Ultrasound Obstet Gynecol 2001;17(5):370–379
18. Boyd PA, Chamberlain P, Hicks NR. 6-year experience of prenatal diagnosis in an unselected population in Oxford, UK. Lancet 1998;352(9140):1577–1581
19. Chitty LS, Hunt GH, Moore J, Lobb MO. Effectiveness of routine ultrasonography in detecting fetal structural abnormalities in a low risk population. BMJ 1991;303(6811):1165–1169
20. Levi S, Hyjazi Y, Schaaps JP, Deffoort P, Coulon R, Bueckens P. Sensitivity and specificity of routine antenatal screening for congenital anomalies by ultrasound: the Belgian Multicentric Study. Ultrasound Obstet Gynecol 1991;1(2):102–110
21. Levi S, Schaaps JP, De Havay P, Coulon R, Defoort P. End-result of routine ultrasound screening for congenital anomalies: the Belgian Multicentric Study 1984–92. Ultrasound Obstet Gynecol 1995;5(6): 366–371
22. Luck CA. Value of routine ultrasound scanning at 19 weeks: a four year study of 8849 deliveries. BMJ 1992;304(6840):1474–1478
23. Saari-Kemppainen A, Karjalainen O, Ylostalo P, Heinonen OP. Ultrasound screening and perinatal mortality: controlled trial of systematic one-stage screening in pregnancy. The Helsinki Ultrasound Trial. Lancet 1990;336(8712):387–391
207
✩ ✩✩✩✩✩✩✩✩✩✩
24. Saari-Kemppainen A, Karjalainen O, Ylostalo P, Heinonen OP. Fetal anomalies in a controlled one-stage ultrasound screening trial. A report from the Helsinki Ultrasound Trial. J Perinat Med 1994;22(4):279–289
25. Rosendahl H, Kivenen S. Antenatal detection of congenital malformations by routine ultrasonography. Obstet Gynecol 1989;73(6):947–951
26. Shirley IM, Bottomley F, Robinson VP. Routine radiographer screening for fetal abnormalities by ultrasound in an unselected low risk population. Br J Radiol 1992;65(775):564–569
27. Whitlow BJ, Chatzipapas IK, Lazanakis ML, Kadir RA, Economides DL. The value of sonography in early pregnancy for the detection of fetal abnormalities in an unselected population. Br J Obstet Gynaecol 1999;106(9):929–936
28. Van Dorsten JP, Hulsey TC, Newman RB,
Ultrasound in obstetrics and gynaecology
Menard MK. Fetal anomaly detection by second-trimester ultrasonography in a tertiary center. Am J Obstet Gynecol 1998;178(4):742–749
29. Smith-Bindman R, Hosmer W, Feldstein VA, Deeks JJ, Goldberg JD. Second­trimester ultrasound to detect fetuses with Down syndrome: a meta-analysis. JAMA 2001;285(8):1044–1055
30. MacLachlan N, Iskaros J, Chitty L. Ultrasound markers of fetal chromosomal abnormality: a survey of policies and practices in UK maternity ultrasound departments. Ultrasound Obstet Gynecol 2000;15(5):387–390
31. Whitby EH, Paley MN, Sprigg A et al. Comparison of ultrasound and magnetic resonance imaging in 100 singleton pregnancies with suspected brain abnormalities. Br J Obstet Gynaecol 2004;111:784–792
32. Von Koch CS, Glenn OA, Goldstein RB, Barkorich AJ. Fetal magnetic resonance imaging enhances detection of spinal cord anomalies in patients with sonographically detected bony anomalies of the spine. J Ultrasound Med 2005;24:781–789
33. Goldstein I, Copel JA, Makhoul IR. Mild cerebral ventriculomegaly in foetuses: characteristicts and outcome. Fetal Diagn Ther 2005;20:281–284
34. Gaglioti P, Danelon D, Bontempo S et al. Fetal cerebral ventriculomegaly: outcome in 176 cases. Ultrasound Obstet Gynecol 2005;25:372–377
35. Bernier FP, Crawford SG, Dewey D. Developmental outcome of children who had choroid plexus cysts detected prenatally. Prenat Diagn 2005;25:322–326
36. Pajkrt E, Weisz B, Firth HV, Chitty LS. Fetal cardiac anomalies and genetic syndromes. Prenat Diagn 2004;24:1104–1115
37. Allan L, Benacerraf B, Cope L JA et al. Isolated major congenital heart disease. Ultrasound Obstet Gynecol 2001;17:370–379
38. Mohan UR, Kleinman CS, Kern JH. Fetal echocardiography and its evolving impact 1992 to 2002. Am J Cardiol 2005;96: 134–136
39. Sharland G. Routine fetal cardiac screening: what are we doing and what should we do? Prenal Diagn 2004;24:1123–1129
40. Goncalves LF, Lee W, Chaiworaponga T et al. Four-dimensional ultrasonography of the fetal heart with spatiotemporal image correlation. Am J Obstet Gynecol 2003;189:1792–1802
41. Wiesel A, Queisser-Luft A, Clementi M, Bianca S, Stoll C, Euroscan Study Group. Prenatal detection of congenital renal malformations by fetal ultrasonographic examination: an analysis of 709,030 births in 12 European countries. Eur J Med Gen 2005;48:131–144
42. Damen-Elias HA, De Jong TP, Stigter RH, Visser GH, Stoutenback PH. Congenital renal tract anomalies: outcome and follow up of 402 cases detected antenatal between 1986 and 2001. Ultrasound Obstet Gynecol 2005;25:134–143
43. Van Eijk L, Cohen-Overbeek TE, den Hollander NS, Nijman JM, Wladimiroff JW. Unilateral multicystic kidney: a combined pre- and postnatal assessment ultrasound. Obstet Gynecol 2002;19:180–183
44. Cohen-Overbeek TE, Wijngaard-Boom P, Ursem NT, Hop WC, Wladimiroff JM, Wolffenbuttel KP. Mild renal pyelectasis in the second trimester: determination of cut­off levels for postnatal referral ultrasound. Obstet Gynecol 2005;25:375–383
208
11
✩✩✩✩✩✩✩✩✩✩✩✩✩✩✩✩✩✩✩✩ ✩

Evaluation of fetal and uteroplacental blood flow

Annegret Geipel Ulrich Gembruch
ABSTRACT
Doppler application in modern obstetric practice has been expanded widely. Flow velocity waveforms of maternal and fetal vessels provide important diagnostic and prognostic information with respect to a variety of pregnancy complications. Impaired placentation, as depicted by uterine Doppler sonography, is associated with an increased risk for the development of pre-eclampsia and/or growth restriction. Doppler information of fetal systemic vessels helps the obstetrician in managing pregnancies complicated by intrauterine growth restriction. Longitudinal observations of fetal Doppler changes in growth-restricted fetuses demonstrate progressive deterioration of umbilical artery blood flow, followed by middle cerebral artery velocimetry and finally ductus venosus blood flow. Doppler signal characteristics aid in the decision on when to time the delivery. Further, the rate and degree of deteriorating Doppler signals are closely related to the risks for adverse perinatal outcome. The Doppler assessment of middle cerebral artery peak systolic velocity is increasingly used in the surveillance of fetuses at risk for anaemia, thus avoiding the need for invasive procedures. Doppler is also an invaluable contributor in managing pregnancies complicated by heart disease or twin–twin transfusion syndrome.
KEYWORDS
Ductus venosus, fetal anaemia, fetal Doppler, fetal growth restriction, middle cerebral artery, pre-eclampsia, twin–twin transfusion syndrome, umbilical artery, uteroplacental blood flow, venous Doppler.

INTRODUCTION

Doppler ultrasound assessment of the placental and fetal circulations plays an important role in modern antenatal care. Uterine Doppler investigation is a
209
✩ ✩✩✩✩✩✩✩✩✩✩
screening tool for impaired placentation and its complications of pre-eclampsia, fetal growth restriction and placental abruption. Doppler ultrasonography of fetal vessels (umbilical artery, middle cerebral artery, ductus venosus) helps in the diag­nosis and management of a wide range of pathological conditions, such as fetal growth restriction (FGR), fetal anaemia, twin–twin transfusion syndrome (TTTS) and fetal cardiac disease. Table 11.1 summarizes important topics of Doppler application in pregnancy. As illustrated there, fetomaternal Doppler evaluation is part of first- and second-trimester screening programmes in low- and high­risk pregnancies, the latter defined by history and by diagnosis of anatomical or growth abnormalities in these examinations.
In clinical practice, arterial flow velocity waveforms are quantified by the use
of indices. The advantage of indices compared to absolute velocities is that they
Table 11.1 Indications for Doppler application in pregnancy
Ultrasound in obstetrics and gynaecology
Indication Gestational age Vessel Parameter
Detailed first trimester screening – advanced maternal age – increased nuchal
translucency
History of – pre-eclampsia/PIH/ placental abruption – IUFD/ severe FGR
Maternal vascular disease – lupus erythematodes/ antiphospholipid/ antibodies/thrombophilia – hypertension – diabetes mellitus
Abnormal fetal growth – small for dates/FGR – proved FGR
Risk of fetal anaemia – red cell alloimmunization – parvovirus infection
Twin pregnancy – discordant growth – TTTS/TRAP sequence
Fetal abnormality – cardiac disease/ arrhythmia – fetal hydrops
12–14 weeks DV a-wave (positive/
18–22 weeks uterine artery notching, PI/RI
18–22 weeks uterine artery notching, PI/RI
2nd/3rd trimester uterine artery
UA (1st), MCA (2nd) UA, MCA, DV
2nd/3rd trimester MCA PSV
2nd/3rd trimester uterine artery
UA (1st), MCA (2nd) UA, MCA, DV
2nd/3rd trimester UA, MCA, DV
fetal echocardiography
negative)
notching, PI/RI PI/RI PI/RI, PVIV/PIV
notching, PI/RI PI/RI PI/RI, MCA PSV, PVIV/PIV
PI/RI, MCA PSV, PVIV/PIV
210
DV, ductus venosus; FGR, fetal growth restriction; IUFD, intrauterine fetal death; MCA, middle cerebral artery; PIH, pregnancy-induced hypertension, PI, pulsatility index; PIV, pulsatility index for veins; PSV, peak systolic velocity, PVIV, peak velocity index for veins, RI, resistance index; TRAP, twin reversed arterial perfusion; TTTS, twin–twin transfusion syndrome; UA, umbilical artery.
✩✩✩✩✩✩✩✩✩✩ ✩
Pulsatility Index (PI)
PI =
A Arterial Doppler (umbilical artery)
S D
T
AMX
PI = = 1.2
30 9
17
Resistance Index (RI)
RI =
S D
S
RI = = 0.7
30 9
30
Systolic/ Diastolic Ratio
S/ D Ratio =
S D
S/ D =
30
9
= 3.3
Peak Velocity Index for Veins (PVIV)
Pulsatility Index for Veins (PIV)
PVIV = PVIV =
S A
D
= 0.49
65 34
63
PIV = PIV =
S A
T
AMX
= 0.59
65 34
52
B Venous Doppler (ductus venosus)
are angle independent. For the assessment of true velocities, an angle of insonation close to 0 ° is desired, as otherwise with increasing angle the blood velocity is progressively underestimated or increasingly incorrect if the function of angle correction is used. Commonly used downstream indices that represent mainly the impedance of the distal vascular bed are:
pulsatility index (PI)
•
resistance index (RI)
•
S/D ratio.
•
The calculation of these indices is demonstrated in Figure 11.1. The use of the PI has the advantage of a wider spectrum of values in cases with no end-diastolic flow component. In addition to the various indices, blood flow can be categorized according to a particular waveform pattern, such as the presence or absence of an end-diastolic component or of an end-diastolic notch. In general, a low-pulsatility waveform represents a low distal resistance (e.g. normal uterine artery Doppler) and
Evaluation of fetal and uteroplacental blood flow
Figure 11.1 Calculation of commonly used Doppler indices. (A) Arterial Doppler (umbilical artery). (B) Venous Doppler (ductus venosus).
211
✩ ✩✩✩✩✩✩✩✩✩✩
a high-pulsatility waveform indicates high peripheral resistance (e.g. normal middle cerebral Doppler). Impedance to flow of the ductus venosus, the venae cavae or the hepatic veins can be calculated by the following indices (see Fig. 11.1):
pulsatility index for veins (PIV)
•
peak velocity index for veins (PVIV).
•

UTERINE ARTERY DOPPLER

The impedance to flow in the uterine arteries decreases with advancing gestation in normal pregnancies, reflecting the trophoblastic invasion of the spiral arter­ies. This process is complete by about 18 weeks' gestation. In pregnancies with impaired placentation, high uterine vascular resistance will persist after this time (Fig. 11.2). Uterine Doppler screening is commonly performed around 20 weeks of gestation, as a part of the fetal anomaly scan.39 A transabdominal or transvagi­nal approach is possible. Colour Doppler assists in the quick visualization of the uterine artery at its crossing with the external iliac artery. Pulsed-wave Doppler
Ultrasound in obstetrics and gynaecology
is used to obtain 3–5 similar consecutive waveforms from both sides. The wave­form can be analysed by calculating indices (PI, RI) or by assessing the presence or absence of an end-diastolic notch. Impedance of the uterine artery on the placental side is usually lower. In most studies, the mean indices from both ves-
212
sels are calculated. Cut-off values at 23 weeks' gestation are a mean PI above
1.5–1.6 notches after 24 weeks' gestation also represents high uterine resistance and is considered abnormal. Bilateral notches are found in about 25–30% of pregnancies at 12 weeks, 10–15% at 20 weeks and 5% at 24 weeks. Notch quantification has been suggested, but is rarely used in daily clinical practice. In the case of a later­ally located placenta, blood flow on the placental side is more important. While a notch on the non-placental side is of reduced significance, the presence of an ipsilateral notch is of high importance.
fusion have demonstrated that high impedance to flow in the second trimester is associated with a higher risk of pre-eclampsia, FGR or placental abruption. The optimum gestational age for uterine screening studies is considered to be 20– 24 weeks of gestation, providing the best sensitivity/specificity trade-off. Increased impedance to flow in the uterine arteries will identify about 40–50% of the preg­nancies that will subsequently develop pre-eclampsia and approximately 30% of those that will develop FGR. More importantly, abnormal uterine Doppler wave­forms perform better in predicting severe, early-onset complications. The sensi­tivity of uterine Doppler screening for pre-eclampsia and FGR requiring delivery before 34 weeks' gestation is about 80% and 60–70%, respectively (Table 11.2). Another important finding of those studies is the high negative predictive value of 98–99% for pre-eclampsia and 93–95% for FGR. This finding might aid in stratifying a more risk-orientated antenatal care approach. Women with normal uterine Doppler findings are unlikely to develop early pre-eclampsia or FGR and
1,38
or a mean RI above 0.57–0.58.
Over the last 25 years a number of Doppler studies on the uteroplacental per-
17,28
The persistence of bilateral
✩✩✩✩✩✩✩✩✩✩ ✩
Evaluation of fetal and uteroplacental blood flow
Figure 11.2 Uterine artery Doppler. (A) Normal impedance to flow at 22 weeks' gestation. (B) Increased impedance to flow with end-diastolic notching at 24 weeks.
213